Publications for John Gibson
Publications for John Gibson
2016
Bryant, C., Fromm, P., Kupresanin, F., Clark, G.,
Lee, K., Clarke, C., Silveira, P., Suen, H.,
Brown, R., Newman, E., Hart, D., et al (2016). A
CD2 high-expressing stress-resistant human
plasmacytoid dendritic-cell subset. Immunology
and Cell Biology, 94(5), 447-457. <a
href="http://dx.doi.org/10.1038/icb.2015.116">[
More Information]</a>
2015
Uy, G., Costa, L., Hari, P., Zhang, M., Huang, J.,
Anderson, K., Bredeson, C., Callander, N.,
Cornell, R., Gibson, J., et al (2015). Contribution
of chemotherapy mobilization to disease control
in multiple myeloma treated with autologous
hematopoietic cell transplantation. Bone Marrow
Transplantation, 50(12), 1513-1518. <a
href="http://dx.doi.org/10.1038/bmt.2015.190">[
More Information]</a>
Urbano-Ispizua, A., Pavletic, S., Flowers, M.,
Klein, J., Zhang, M., Carreras, J., Montoto, S.,
Perales, M., Aljurf, M., Akpek, G., et al (2015).
The Impact of Graft Versus Host Disease on
Relapse Rate in Patients with Lymphoma
Depends on the Histological Sub-Type and the
Intensity of the Conditioning Regimen. Biology
of Blood and Marrow Transplantation, 21(10),
1746-1753. <a
href="http://dx.doi.org/10.1016/j.bbmt.2015.05.0
10">[More Information]</a>
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer,
A., Harrison, S., Mollee, P., Roberts, A.,
Horvath, N., Talulikar, D., Gibson, J., et al
(2015). Treatment of patients with multiple
myeloma who are eligible for stem cell
transplantation: Position statement of the
Myeloma Foundation of Australia Medical and
Scientific Advisory Group. Internal Medicine
Journal, 45(1), 94-105. <a
href="http://dx.doi.org/10.1111/imj.12640">[Mo
re Information]</a>
Quach, H., Joshua, D., Ho, J., Szer, J., Spencer,
A., Harrison, S., Mollee, P., Roberts, A.,
Horvath, N., Talaulikar, D., Gibson, J., et al
(2015). Treatment of patients with multiple
myeloma who are not eligible for stem cell
transplantation: position statement of the
myeloma foundation of Australia Medical and
Scientific Advisory Group. Internal Medicine
Journal, 45(3), 335-343. <a
href="http://dx.doi.org/10.1111/imj.12688">[Mo
re Information]</a>
Brown, R., McAuliffe, S., Catalano, A., Ho, J.,
Nassif, N., Woodland, N., Hart, D.,
Weatherburn, C., Yang, S., Suen, H., Joshua, D.,
et al (2015). Using digital polymerase chain
reaction to detect minimal residual disease in
myeloma by identifying FGFR3 up-regulation.
Leukemia & Lymphoma, 56(9), 2714-2716. <a
href="http://dx.doi.org/10.3109/10428194.2014.
1003061">[More Information]</a>
2014
Favaloro, J., Liyadipitiya, T., Brown, R., Yang,
S., Suen, H., Woodland, N., Nassif, N., Hart, D.,
Fromm, P., Weatherburn, C., Joshua, D., et al
(2014). Myeloid derived suppressor cells are
numerically, functionally and phenotypically
different in patients with multiple myeloma.
Leukemia & Lymphoma, 55(12), 2893-2900. <a
href="http://dx.doi.org/10.3109/10428194.2014.
904511">[More Information]</a>
Favaloro, J., Brown, R., Aklilu, E., Yang, S.,
Suen, H., Hart, D., Fromm, P., Gibson, J., Khoo,
L., Ho, J., Joshua, D. (2014). Myeloma skews
regulatory T and pro-inflammatory T helper 17
cell balance in favor of a suppressive state.
Leukemia & Lymphoma, 55(5), 1090-1098. <a
href="http://dx.doi.org/10.3109/10428194.2013.
825905">[More Information]</a>
Wright, C., Velickovic, Z., Brown, R., Larsen,
S., Macpherson, J., Gibson, J., Rasko, J. (2014).
Raising the standard: changes to the Australian
Code of Good Manufacturing Practice (cGMP)
for human blood and blood components, human
tissues and human cellular therapy products.
Pathology, 46(3), 177-183. <a
href="http://dx.doi.org/10.1097/PAT.000000000
0000067">[More Information]</a>
2013
Talbot, J., Martin, P., Johnson, L., Beatty, J.,
Sutton, D., Halliday, C., Gibson, J., Kiddell, L.,
Steiner, J., Ujvari, B., Barrs, V. (2013). A
molecular approach to identification of species
causing sinonasal aspergillosis. The Australian
Society for Microbiology, Annual Scientific
Meeting.
Hamadani, M., Saber, W., Ahn, K., Carreras, J.,
Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale,
G., Hari, P., et al (2013). Allogeneic
hematopoietic cell transplantation for
chemotherapy-unresponsive mantle cell
lymphoma: a cohort analysis from the center for
international blood and marrow transplant
research. Biology of Blood and Marrow
Transplantation, 19(4), 625-631. <a
href="http://dx.doi.org/10.1016/j.bbmt.2013.01.0
09">[More Information]</a>
Maziarz, R., Wang, Z., Zhang, M., Bolwell, B.,
Chen, A., Fenske, T., Freytes, C., Gale, R.,
Gibson, J., Hayes-Lattin, B., et al (2013).
Autologous haematopoietic cell transplantation
for non-Hodgkin lymphoma with secondary CNS
involvement. British Journal of Haematology,
Publications for John Gibson
162(5), 648-656. <a
href="http://dx.doi.org/10.1111/bjh.12451">[Mo
re Information]</a>
Hamadani, M., Saber, W., Ahn, K., Carreras, J.,
Cairo, M., Fenske, T., Gale, R., Gibson, J., Hale,
G., Hari, P., et al (2013). Impact of
pretransplantation conditioning regimens on
outcomes of allogeneic transplantation for
chemotherapy-unresponsive diffuse large B cell
lymphoma and grade III follicular lymphoma.
Biology of Blood and Marrow Transplantation,
19(5), 746-753. <a
href="http://dx.doi.org/10.1016/j.bbmt.2013.01.0
24">[More Information]</a>
(2012). CD86+ or HLA-G+ can be transferred
via trogocytosis from myeloma cells T cells and
are associated with poor prognosis. Blood,
120(10), 2055-2063. <a
href="http://dx.doi.org/10.1182/blood-2012-03-4
16792">[More Information]</a>
Chohan, G., Barnett, Y., Gibson, J., Reddel, S.,
Barnett, M. (2012). Langerhans cell histiocytosis
with refractory central nervous system
involvement responsive to infliximab. Journal of
Neurology, Neurosurgery, and Psychiatry, 83(5),
573-575. <a
href="http://dx.doi.org/10.1136/jnnp-2011-30057
5">[More Information]</a>
Gibson, J., Iland, H., Larsen, S., Brown, C.,
Joshua, D. (2013). Leukaemias into the 21st
century - part 2: the chronic leukaemias. Internal
Medicine Journal, 43(5), 484-494. <a
href="http://dx.doi.org/10.1111/imj.12135">[Mo
re Information]</a>
Brown, C., Larsen, S., Iland, H., Joshua, D.,
Gibson, J. (2012). Leukaemias into the 21st
century: part 1: the acute leukaemias. Internal
Medicine Journal, 42(11), 1179-1186. <a
href="http://dx.doi.org/10.1111/j.1445-5994.201
2.02938.x">[More Information]</a>
Bryant, C., Suen, H., Brown, R., Yang, S.,
Favaloro, J., Aklilu, E., Gibson, J., Ho, J., Iland,
H., Fromm, P., Hart, D., Joshua, D., et al (2013).
Long-term survival in multiple myeloma is
associated with a distinct immunological profile,
which includes proliferative cytotoxic T-cell
clones and a favourable Treg/Th17 balance.
Blood Cancer Journal, 3, 1-7. <a
href="http://dx.doi.org/10.1038/bcj.2013.34">[M
ore Information]</a>
Gibson, J., Weatherburn, C. (2012).
Polycythaemia. Medical Observer, 21st August
2012.
Gasiorowski, R., Gibson, J., Watson, G.,
Trotman, J., Larsen, S. (2013). Rapidly fatal
post-allogeneic stem cell transplant
lymphoproliferative disorder presenting with
skin and bone marrow involvement. Pathology,
45(1), 81-83. <a
href="http://dx.doi.org/10.1097/PAT.0b013e328
35b5de4">[More Information]</a>
Michaelis, L., Saad, A., Zhong, X.,
Le-Rademacher, J., Freytes, C., Marks, D.,
Lazarus, H., Bird, J., Holmberg, L., Kamble, R.,
et al (2013). Salvage second hematopoietic cell
transplantation in myeloma. Biology of Blood
and Marrow Transplantation, 19(5), 760-766. <a
href="http://dx.doi.org/10.1016/j.bbmt.2013.01.0
04">[More Information]</a>
Ahmed, R., King, J., Gibson, J., Buckland, M.,
Gupta, R., Gonzales, M., Halmagyi, M. (2013).
Spinal Leptomeningeal Lymphoma presenting as
Pseudotumor Syndrome. Journal of
Neuro-Ophthalmology, 33(1), 13-16. <a
href="http://dx.doi.org/10.1097/WNO.0b013e31
823ff460">[More Information]</a>
2012
Brown, R., Karieshma, K., Favaloro, J., Yang,
S., Joy Ho, P., Gibson, J., Fromm, P., Suen, H.,
Woodland, N., Nassif, N., Hart, D., Joshua, D.
Ho, J., Brown, R., Spencer, A., Jeffels, M.,
Daniher, D., Gibson, J., Joshua, D. (2012).
Thalidomide consolidation improves
progression-free survival in myeloma with
normal but not up-regulated expression of
fibroblast growth factor receptor 3: analysis from
the Australasian Leukaemia and Lymphoma
Group MM6 clinical trial. Leukemia &
Lymphoma, 53(9), 1728-1734. <a
href="http://dx.doi.org/10.3109/10428194.2012.
664842">[More Information]</a>
Brown, R., Suen, H., Favaloro, J., Yang, S., Ho,
P., Gibson, J., Joshua, D. (2012). Trogocytosis
generates acquired regulatory T cells adding
further complexity to the dysfunctional immune
response in multiple myeloma.
OncoImmunology, 1(9), 1658-1660. <a
href="http://dx.doi.org/10.4161/onci.22032">[M
ore Information]</a>
2011
Nivison-Smith, I., Dodds, A., Doocey, R., Ganly,
P., Gibson, J., Ma, D., Simpson, J., Szer, J.,
Bradstock, K., Bradstock, K. (2011). Allogeneic
hematopoietic cell transplant for multiple
myeloma using reduced intensity conditioning
therapy, 1998-2006: factors associated with
improved survival outcome. Leukemia &
Lymphoma, 52(9), 1727-1735. <a
href="http://dx.doi.org/10.3109/10428194.2011.
582201">[More Information]</a>
Passweg, J., Zhang, M., Rocha, V., Kan, F.,
Champlin, R., Isola, L., Gee, A., Gibson, J.,
Laughlin, M., Lazarus, H., et al (2011). Donor
Characteristics Affecting Graft Failure,
Publications for John Gibson
Graft-versus-Host Disease, and Survival after
Unrelated Donor Transplantation with
Reduced-Intensity Conditioning for Hematologic
Malignancies. Biology of Blood and Marrow
Transplantation, 17(12), 1869-1873. <a
href="http://dx.doi.org/10.1016/j.bbmt.2011.07.0
08">[More Information]</a>
Vogl, D., Wang, T., Perez, W., Stadtmauer, E.,
Heitjan, D., Lazarus, H., Kyle, R., Kamble, R.,
Weisdorf, D., Roy, V., Gibson, J., et al (2011).
Effect of obesity on outcomes after autologous
hematopoietic stem cell transplantation for
multiple myeloma. Biology of Blood and
Marrow Transplantation, 17(12), 1765-1774. <a
href="http://dx.doi.org/10.1016/j.bbmt.2011.05.0
05">[More Information]</a>
Khoo, T., Vangsted, A., Joshua, D., Gibson, J.
(2011). Interferon-Alpha in the Treatment of
Multiple Myeloma. Current Drug Targets
(online), 12(3), 437-446. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=21143148">[More Information]</a>
Brown, R., Langshaw, M., Uhr, E., Gibson, J.,
Joshua, D. (2011). The impact of mandatory
fortification of flour with folic acid on the blood
folate levels of an Australian population.
Medical Journal of Australia, 194(2), 65-67. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=21241218">[More Information]</a>
2010
Suryani, S., Fulcher, D., Nanan, B., Nanan, R.,
Wong, M., Shaw, P., Gibson, J., Williams, A.,
Tangye, S. (2010). Differential expression of
CD21 identifies developmentally and
functionally distinct subsets of human
transitional B cells. Blood, 115(3), 519-529. <a
href="http://dx.doi.org/10.1182/blood-2009-07-2
34799">[More Information]</a>
Reece, D., Vesole, D., Shrestha, S., Zhang, M.,
Perez, W., Dispenzieri, A., Milone, G., Abidi,
M., Atkins, H., Bashey, A., Gibson, J., et al
(2010). Outcome of Patients With IgD and IgM
Multiple Myeloma Undergoing Autologous
Hematopoietic Stem Cell Transplantation: A
Retrospective CIBMTR Study. Clinical
Lymphoma, Myeloma and Leukemia, 10(6),
458-463. <a
href="http://dx.doi.org/10.3816/CLML.2010.n.0
78">[More Information]</a>
Hari, P., Majhail, N., Zhang, M., Hassebroek, A.,
Siddiqui, F., Ballen, K., Bashey, A., Bird, J.,
Freytes, C., Gibson, J., et al (2010). Race and
Outcomes of Autologous Hematopoietic Cell
Transplantation for Multiple Myeloma. Biology
of Blood and Marrow Transplantation, 16(3),
395-402. <a
href="http://dx.doi.org/10.1016/j.bbmt.2009.11.0
07">[More Information]</a>
2009
Brown, R., Spencer, A., Ho, J., Kennedy, N.,
Kabani, K., Yang, S., Sze, D., Aklilu, E., Gibson,
J., Joshua, D. (2009). Prognostically significant
cytotoxic T cell clones are stimulated after
thalidomide therapy in patients with multiple
myeloma. Leukemia & Lymphoma, 50(11),
1860-1864. <a
href="http://dx.doi.org/10.3109/1042819090321
6804">[More Information]</a>
Devetten, M., Hari, P., Carreras, J., Logan, B.,
van Besien, K., Bredeson, C., Freytes, C., Gale,
R., Gibson, J., Giralt, S., et al (2009). Unrelated
Donor Reduced-Intensity Allogeneic
Hematopoietic Stem Cell Transplantation for
Relapsed and Refractory Hodgkin Lymphoma.
Biology of Blood and Marrow Transplantation,
15(1), 109-117. <a
href="http://dx.doi.org/10.1016/j.bbmt.2008.11.0
11">[More Information]</a>
2008
Kumar, S., Perez, W., Zhang, M., Ballen, K.,
Bashey, A., To, L., Bredeson, C., Cairo, M.,
Elfenbein, G., Freytes, C., et al (2008).
Comparable outcomes in nonsecretory and
secretory multiple myeloma after autologous
stem cell transplantation. Biology of Blood and
Marrow Transplantation, 14(10), 1134-1140. <a
href="http://dx.doi.org/10.1016/j.bbmt.2008.07.0
11">[More Information]</a>
Bashey, A., Perez, W., Zhang, M., Anderson, K.,
Ballen, K., Berenson, J., To, L., Fonseca, R.,
Freytes, C., Gale, R., et al (2008). Comparison of
twin and autologous transplants for multiple
myeloma. Biology of Blood and Marrow
Transplantation, 14(10), 1118-1124. <a
href="http://dx.doi.org/10.1016/j.bbmt.2008.07.0
07">[More Information]</a>
Joshua, D., Brown, R., Gibson, J. (2008).
Regulatory T cells and Multiple Myeloma.
Clinical Lymphoma & Myeloma, 8(5), 283-286.
<a
href="http://dx.doi.org/10.3816/CLM.2008.n.039
">[More Information]</a>
Burgess, P., Robin, H., Langshaw, M., Kershaw,
G., Pathiraja, R., Yuen, S., Coad, C., Xiros, N.,
Mansy, G., Coleman, R., Gibson, J., Joshua, D.,
et al (2008). Rule based processing of the
CD4000, CD3200 and CD Sapphire analyser
output using the Cerner Discern Expert Module.
International Journal of Laboratory
Hematology, 31(6), 603-614. <a
href="http://dx.doi.org/10.1111/j.1751-553X.200
8.01085.x">[More Information]</a>
Publications for John Gibson
2007
Grigg, A., Gibson, J., Bardy, P., Reynolds, J.,
Shuttleworth, P., Koelmeyer, R., Szer, J.,
Roberts, A., To, L., Kennedy, G., Bradstock, K.
(2007). A prospective multicenter trial of
peripheral blood stem cell sibling allografts for
acute myeloid leukemia in first complete
remission using fludarabine-cyclophosphamide
reduced intensity conditioning. Biology of Blood
and Marrow Transplantation, 13(5), 560-567. <a
href="http://dx.doi.org/10.1016/j.bbmt.2006.12.4
49">[More Information]</a>
Loh, Y., Mo, S., Brown, R., Yamagishi, T.,
Yang, S., Joshua, D., Ho, P., Gibson, J.,
Roufogalis, B., Sze, D. (2007). Characteristics of
'side population' as the putative cancer stem cells
in myeloma: Cell growth and differentiation
capability. Molecular Cancer Therapeutics,
6(12), 3365s-3366s.
Sanders, J., Crawford, B., Gibson, J., Ho, J.,
Iland, H., Joshua, D. (2007). Is there a case for
the early use of bisphosphonates in smouldering
myeloma and MGUS? (Bisphosphonates in
SMM & MGUS). International Journal of
Laboratory Hematology, 29(5), 395-397. <a
href="http://dx.doi.org/10.1111/j.1365-2257.200
6.00860.x">[More Information]</a>
Ling, S., Campbell, L., Ho, J., Gibson, J., Joshua,
D. (2007). Molecular Biology, Pathology, and
Cytogenetics. In Mikkael A. Sekeres, Matt E.
Kalaycio, Brian J. Bolwell (Eds.), Clinical
Malignant Haematology, (pp. 847-857). United
States: McGraw Hill.
Feyler, S., Prince, H., Pearce, R., Towlson, K.,
Nivison-Smith, I., Schey, S., Gibson, J., Patton,
N., Bradstock, K., Marks, D., et al (2007). The
role of high-dose therapy and stem cell rescue in
the management of T-cell malignant lymphomas:
a BSBMT and ABMTRR study. Bone Marrow
Transplantation, 40(5), 443-450. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17589529">[More Information]</a>
Joshua, D., Brown, R., Sze, D., Hodges, P.,
Gibson, J. (2007). The role of T-cells in
myeloma. XIth International Myeloma Workshop
& IVth International Workshop on
Waldenstrom’s Macroglobulinemia, Italy:
Fondazione Ferrata Storti.
2006
Gibson, J., Anagnostopoulos, A., Hari, P., Pérez,
W., Ballen, K., Bashey, A., Bredeson, C.,
Freytes, C., Gale, R., Gertz, M., et al (2006).
Autologous or allogeneic stem cell
transplantation in patients with Waldenstrom's
macroglobulinemia. Biology of Blood and
Marrow Transplantation, 12(8), 845-854. <a
href="http://dx.doi.org/10.1016/j.bbmt.2006.04.0
10">[More Information]</a>
Sze, D., Brown, R., Yang, S., Ho, J., Gibson, J.,
Joshua, D. (2006). The use of thalidomide in
myeloma therapy as an effective anticancer drug.
Current Cancer Drug Targets, 6(4), 325-331. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=16848723">[More Information]</a>
Ling, S., Joshua, D., Gibson, J., Young, G.,
Iland, H., Watson, G., Ho, J. (2006).
Transformation and Progression of
Waldenström's Macroglobulinemia Following
Cladribine Therapy in Two Cases: Natural
Evolution or Iatrogenic Causation? American
Journal Of Hematology, 81(2), 110-114. <a
href="http://dx.doi.org/10.1002/ajh.20475">[Mo
re Information]</a>
2005
Gibson, J., Joshua, D., Ho, J., Campbell, L.,
Ling, S. (2005). Multiple Myeloma: molecular
biology, Pathology and Cytogenics. In Susan
Hallam, Ian Cross, Michael Thaut (Eds.), Oxford
Handbook of Music Psychology. Oxford, UK:
Oxford University Press.
Gibson, J., Prosser, I., Spencer, A., Horvath, N.,
Prince, R., Herrmann, R., Bashford, J., Joske, D.,
Grigg, A., McKendrick, J., et al (2005).
Prospective randomised trial of amifostine
cytoprotection in myeloma patients undergoing
high-dose melphalan conditioned autologous
stem cell transplantation. Bone Marrow
Transplantation, 35(10), 971-7. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15778725">[More Information]</a>
2004
Brown, R., Murray, A., Pope, B., Sze, D.,
Gibson, J., Ho, J., Joshua, D. (2004). B7+ T
Cells In Myeloma: An Acquired Marker Of Prior
Chronic Antigen Presentation. Leukemia and
Lymphoma, 45(2), 363-371.
Brown, R., Murray, A., Pope, B., Sze, D.,
Gibson, J., Ho, J., Hart, D., Joshua, D. (2004).
Either Interleukin-12 Or Interferon-γ Can
Correct The Dendritic Cell Defect Induced By
Transforming Growth Factor β�? In Patients
With Myeloma. British Journal of Haematology,
125(2), 743-748.
Gibson, J., Ho, J., Joshua, D. (2004). Evolving
Transplant Options For Multiple Myeloma:
Autologous And Nonmyeloablative Allogenic.
Transplantation Proceedings, 36(8), 2501-2503.
<a
href="http://dx.doi.org/10.1016/j.transproceed.20
04.06.033">[More Information]</a>
Publications for John Gibson
Mollee, P., Arthur, C., Hughes, T., Januszewicz,
H., Grigg, A., Bradstock, K., Wolf, M., Gibson,
J., Schwarer, A., Spencer, A., et al (2004).
Interferon-Alpha-2B And Oral Cytarabine
Ocfosfate For Newly Diagnosed Chronic
Myeloid Leukaemia. Annals of Oncology,
15(12), 1810-1815.
Horvath, N., Hahn, U., Joshua, D., Dyson, P.,
Gibson, J., Stevens, J., Rawling, T., Barrow, L.,
Brown, R., Stephens, S., et al (2004). Long-Term
Follow Up Of Sequential Mobilisation And
Autologous Transplantation With Cd34-Selected
Cells In Multiple Myeloma: A Multimodality
Approach. Internal Medicine Journal, 34,
167-175.
Gibson, J., Ho, J., Joshua, D. (2004). Low-Grade
Lymphoma: The Optimal Timing.
Transplantation Proceedings, 36(7), 1995-1998.
<a
href="http://dx.doi.org/10.1016/j.transproceed.20
04.06.034">[More Information]</a>
Szer, J., Durrant, S., Schwarer, A., Bradstock,
K., Gibson, J., Arthur, C., To, L., Hughes, T.,
Raunow, H. (2004). Oral Versus Intravenous
Ganciclovir For The Prophylaxis Of
Cytomegalovirus Disease After Allogeneic Bone
Marrow Transplantation. Internal Medicine
Journal, 34(3), 98-101.
Joshua, D., Gibson, J., Brown, R., Ho, J. (2004).
The Immune System In Myeloma. In Gosta
Garton, Brian Durie, Diana Samson (Eds.),
Multiple myeloma and related disorders, (pp.
29-46). UK: Hodder Arnold.
Ho, J., Gibson, J., Joshua, D. (2004). Treatment
Of Multiple Myeloma: Current Management
And New Approaches. American Journal of
Cancer, 3(1), 47-66.
2003
Sze, D., Brown, R., Yuen, E., Gibson, J., Ho, J.,
Raitakari, M., Basten, A., Joshua, D., Fazekas de
St Groth, B. (2003). Clonal Cytotoxic T Cells in
Myeloma. Leukemia and Lymphoma, 44(10),
1667-1674.
Barrow, L., Brown, R., Murray, A., Sze, D.,
POPE, B., Gibson, J., Hart, D., Joshua, D.
(2003). CMRF44+ Dendritic Cells from
Peripheral Blood Stem Cell Harvests of Patients
with Myeloma as Potential Cellular Vectors for
Idiotype Vaccination. Leukemia and Lymphoma,
44(12), 2117-2122.
Gibson, J., et, A. (2003). Comparison of
autologous and allogeneic hematopoietic stem
cell transplantation for follicular lymphoma.
Blood, 102(10), 3521-3529.
Sze, D., Brown, R., Yang, S., Gibson, J., Ho, J.,
Fazekas de St Groth, B., Basten, A., Joshua, D.
(2003). Prediction of high affinity class
I-restricted multiple myeloma idiotype peptide
epitopes. Leukemia and Lymphoma, 44(9),
1557-1568.
Raitakari, M., Brown, R., Gibson, J., Joshua, D.
(2003). T cells in myeloma. Hematological
Oncology, 21(1), 33-42. <a
href="http://dx.doi.org/10.1002/hon.704">[More
Information]</a>
2002
Ho, J., Gibson, J., Joshua, D., Campbell, L.,
Brown, R. (2002). The biology and cytogenetics
of multiple myeloma. Reviews in Clinical and
Experimental Hematology, 6(3), 276-300.
2001
Nivison-Smith, I., Bradstock, K., Szer, J.,
Durrant, S., Dodds, A., Hermann, R., Schwarer,
A., Gibson, J., To, L., Arthur, C. (2001).
Allogeneic haemopoietic cell transplants in
Australia, 1996--a multi-centre retrospective
comparison of the use of peripheral blood stem
cells with bone marrow. Bone Marrow
Transplantation, 28(1), 21-27.
Sze, D., Giesajtis,, G., Brown, R., Raitakari, M.,
Gibson, J., Ho, J., Baxter, A., Fazekas de St
Groth, B., Basten, A., Joshua, D. (2001). Clonal
cytotoxic T cells are expanded in myeloma and
reside in the CD8+Cd57+CD28- compartment.
Blood, 98(9), 2817-2827.
Brown, R., POPE, B., Murray, A., Esdale, W.,
Sze, D., Gibson, J., Ho, J., Hart, D., Joshua, D.
(2001). Dendritic cells from patients with
myeloma are numerically normal but
functionally defective as they fail to up-regulate
CD80 (B7-1) expression after huCD40LT
stimulation because of inhibition by transforming
growth factor-B1 and interleukin-10. Blood,
98(10), 2992-2998.
Ho, J., Basten, A., Gibson, J., Joshua, D., Brown,
R., Pelka, G. (2001). Illegitimate switch
recombinations are present in approximately half
of primary myeloma tumors, but do not relate to
known prognostic indicators or survival. Blood,
97, 490-495.